Quidel Corporation(QDEL)- NASDAQ
  • Thu, Jan. 7, 6:58 PM
    • Quidel (NASDAQ:QDEL) expects Q4 revenue of $52M-$53M, well below a $64M consensus.
    • The company blames lower-than-expected flu-related orders. "According to the Centers for Disease Control and Prevention, the proportion of patients presenting with Influenza-like illness (ILI) in December did not spike in the last few weeks as it has done in many years past ... As a result, the sudden customer ordering that signals the beginning of an Influenza epidemic and often triggers re-ordering by our distribution partners over a two to three week period, has not yet occurred. In fact, in the last few weeks of December, Influenza orders from distribution were roughly one third of what they were in the same period of 2014,"
    • Shares have dropped to $18.00 after hours. Q4 results will arrive in February.
    | Thu, Jan. 7, 6:58 PM
  • Dec. 2, 2014, 1:46 PM
    • Thinly-traded Quidel Corp. (QDEL -10.4%) drops on a 4x surge in volume after the company announced a $150M convertible debt offering after yesterday's close. Pricing and terms have yet to be determined.
    | Dec. 2, 2014, 1:46 PM
  • Dec. 2, 2014, 12:47 PM
    | Dec. 2, 2014, 12:47 PM
  • Dec. 2, 2014, 9:12 AM
    | Dec. 2, 2014, 9:12 AM | 2 Comments
  • Apr. 25, 2012, 6:03 PM
    Quidel (QDEL): Q1 EPS of $0.00 misses by $0.05. Revenue of $38M (-36% Y/Y) misses by $5M. Shares -2.8% AH. (PR)
    | Apr. 25, 2012, 6:03 PM
  • Oct. 26, 2011, 2:42 PM

    Medical diagnostic equipment firms Alere (ALR +14.8%) and Quidel (QDEL +12.4%) are taking off after each posted their Q3 results. Alere's Q3 EPS beat Street estimates by $0.08 on 9% Y/Y revenue growth. Quidel's Q3 EPS missed by $0.05, but its revenue beat estimates by $2.8M, on the back of 17% Y/Y growth. (QDEL transcript)

    | Oct. 26, 2011, 2:42 PM
Company Description
Quidel Corp. develops, manufactures and markets diagnostic testing solutions. Its diagnostic testing solutions include applications in infectious diseases, women's health and gastrointestinal diseases. The company sells its products directly to end users and distributors, in each case, for... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States